Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

PAVmed (PAVM) Cost of Revenue (2022 - 2025)

Historic Cost of Revenue for PAVmed (PAVM) over the last 4 years, with Q3 2025 value amounting to $201000.0.

  • PAVmed's Cost of Revenue changed N/A to $201000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $823000.0, marking a year-over-year change of. This contributed to the annual value of $11.6 million for FY2024, which is 3387.36% down from last year.
  • Per PAVmed's latest filing, its Cost of Revenue stood at $201000.0 for Q3 2025.
  • PAVmed's Cost of Revenue's 5-year high stood at $5.8 million during Q4 2022, with a 5-year trough of $36000.0 in Q3 2024.
  • Moreover, its 4-year median value for Cost of Revenue was $4.2 million (2024), whereas its average is $3.1 million.
  • Its Cost of Revenue has fluctuated over the past 5 years, first surged by 1564.33% in 2023, then crashed by 9669.51% in 2024.
  • Quarter analysis of 4 years shows PAVmed's Cost of Revenue stood at $5.8 million in 2022, then fell by 18.56% to $4.7 million in 2023, then tumbled by 96.7% to $155000.0 in 2024, then grew by 29.68% to $201000.0 in 2025.
  • Its last three reported values are $201000.0 in Q3 2025, $220000.0 for Q2 2025, and $247000.0 during Q1 2025.